Synbiotics as a novel therapeutic approach for hyperphosphatemia and hyperparathyroidism in chronic kidney disease rats

• Published in: Scientific reports Vol. 15; no. 1; pp. 7493 - 10
• Main Authors: Anegkamol, Weerapat, Bowonsomsarit, Wirin, Taweevisit, Mana, Tumwasorn, Somying, Thongsricome, Thana, Kaewwongse, Maroot, Pitchyangkura, Rath, Tosukhowong, Piyaratana, Chuaypen, Natthaya, Dissayabutra, Thasinas
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.03.2025; Nature Publishing Group; Nature Portfolio
• Subjects: 631/326/2565/2134; 692/699/1585/104; 692/699/1585/1732; Animal models; Animals; Bone diseases; Calcification (ectopic); Calcium phosphates; Cardiovascular diseases; Chitosan; Chronic kidney disease; Cisplatin; Disease Models, Animal; Fructooligosaccharides; Humanities and Social Sciences; Hyperparathyroidism; Hyperparathyroidism, Secondary - etiology; Hyperparathyroidism, Secondary - therapy; Hyperphosphatemia; Hyperphosphatemia - blood; Hyperphosphatemia - etiology; Hyperphosphatemia - therapy; Kidney diseases; Male; multidisciplinary; Oligosaccharides - administration & dosage; Paracellular transport; Parathyroid hormone; Parathyroid Hormone - blood; Phosphate; Phosphates - blood; Pre-eclampsia; Probiotics; Rats; Renal Insufficiency, Chronic - chemically induced; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - therapy; Science; Science (multidisciplinary); Synbiotics; Synbiotics - administration & dosage; Tight junction; Tight junction; Chronic kidney disease; Phosphate; Paracellular transport; Synbiotics; Hyperparathyroidism

Hyperphosphatemia and secondary hyperparathyroidism (SHPT) are the common complications found in CKD that lead to severe complications including mineral bone disease (MBD), vascular calcification (VC), and cardiovascular mortality. To mitigate hyperphosphatemia, SHPT and uremic toxemia, we supplemen...